Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Syndax Pharma (NQ: SNDX )

18.98 +0.12 (+0.64%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 687,989
Open 19.19
Bid (Size) 18.70 (1)
Ask (Size) 19.50 (2)
Prev. Close 18.86
Today's Range 18.70 - 19.30
52wk Range 13.14 - 25.34
Shares Outstanding 69,484,053
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
This Sempra Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Via Benzinga
FDA Approves Incyte/Syndax Partnered Drug For Chronic Graft-Versus-Host Disease, A Post-Transplant Complication
The FDA has approved Incyte and Syndax Pharmaceuticals' Niktimvo for chronic graft-versus-host disease in patients after at least two prior therapies, providing new hope for those with this serious... 
Via Benzinga
Exposures Product Safety

Performance

YTD
-13.17%
-13.17%
1 Month
+1.55%
+1.55%
3 Month
-3.46%
-3.46%
6 Month
-15.64%
-15.64%
1 Year
+28.24%
+28.24%

More News

Read More
Incyte and Syndax Announce U.S. FDA Approval of Niktimvo™ (axatilimab-csfr) for the Treatment of Chronic Graft-Versus-Host Disease (GVHD)
From Incyte and Syndax Pharmaceuticals
Via Business Wire
Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors
From Sagimet Biosciences Inc.
Via GlobeNewswire
Syndax Pharmaceuticals: Q4 Earnings Insights
Via Benzinga
Earnings Scheduled For February 27, 2024
Via Benzinga
3 Biotech Stocks That Could Make Your Summer Unforgettable
Via InvestorPlace
Acute Myeloid Leukemia is on the Rise as Biotechs Race to Develop Groundbreaking Therapies
Via FinancialNewsMedia
Pyxis Oncology Expands Board of Directors with Appointment of Michael A. Metzger
From Pyxis Oncology
Via GlobeNewswire
Earnings Preview: Syndax Pharmaceuticals
Via Benzinga
Earnings Outlook For Syndax Pharmaceuticals
Via Benzinga
Analyst Ratings for Syndax Pharmaceuticals
Via Benzinga
Acute Myeloid Leukemia is on the Rise as Biotechs Race to Develop Groundbreaking Therapies
From FN Media Group LLC
Via GlobeNewswire
Why Ooma Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket
Via Benzinga
SNDX Stock Earnings: Syndax Pharmaceuticals Beats EPS for Q1 2024
Via InvestorPlace
Is The Stock Market Ready To Plunge? The Warning Signs Are Here...
Via Talk Markets
What's Going On With Leukemia-Focused Syndax Pharmaceuticals Stock Today?
Via Benzinga
Incyte and Syndax Present Additional Data from Positive AGAVE-201 Trial at ASH Plenary Session Showing Axatilimab Efficacy Including Durable Responses in Chronic Graft-Versus-Host Disease
From Incyte and Syndax Pharmaceuticals
Via Business Wire
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 11, 2023
Via Benzinga
What's Going On With Syndax Pharmaceuticals Stock Monday?
Via Benzinga
Earnings Scheduled For November 2, 2023
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
Via Benzinga
Why AERWINS Technologies Shares Are Trading Higher By Around 90%; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.